Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 991 to 1005 of 1505 results for patients and public

  1. Transperineal laser ablation for treating lower urinary tract symptoms of benign prostatic hyperplasia (IPG798)

    Evidence-based recommendations on transperineal laser ablation for treating lower urinary tract symptoms of benign prostatic hyperplasia. This involves using laser energy to destroy some of the prostate tissue.

    Interventional procedures guidance
    Published
    8 January 2025
    View recommendations

    Sections for IPG798

  2. Laparoscopic insertion of an inactive implant for gastro-oesophageal reflux disease (IPG803)

    Evidence-based recommendations on laparoscopic insertion of an inactive implant for gastro-oesophageal reflux disease. This involves placing an implant on the outside of the upper part of the stomach wall using keyhole surgery.

    Interventional procedures guidance
    Published
    3 June 2025
    View recommendations

    Sections for IPG803

  3. Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides (TA805)

    Evidence-based recommendations on icosapent ethyl (Vazkepa) with statin therapy for reducing the risk of cardiovascular events in adults with raised triglycerides.

    Technology appraisal guidance
    Published
    13 July 2022
    View recommendations

    Sections for TA805

  4. Sleepio to treat insomnia and insomnia symptoms (HTG624)

    Evidence-based recommendations on Sleepio to treat insomnia and insomnia symptoms.

    HealthTech guidance
    Published
    20 May 2022
    View recommendations

    Sections for HTG624

  5. Thoracoscopic aortopexy for severe primary tracheomalacia (IPG243)

    Evidence-based recommendations on thoracoscopic aortopexy for severe primary tracheomalacia. This involves attaching the aorta to the sternum with sutures, using special instruments through small cuts in the chest (keyhole surgery).

    Interventional procedures guidance
    Published
    12 December 2007
    View recommendations

    Sections for IPG243

  6. Severe sialorrhoea (drooling) in children and young people with chronic neurological disorders: oral glycopyrronium bromide (ES5)

    Summary of the evidence on oral glycopyrronium bromide for severe sialorrhoea (drooling) in children and young people with chronic neurological disorders

    Evidence summary
    Published
    14 February 2017

  7. Get involved with HealthTech guidance

    We want you to be involved in our work - whether you’re commenting on our draft recommendations, taking part in guidance development or attending a committee meeting, your voice is important to us.

  8. Port Delivery platform with ranibizumab for treating wet age-related macular degeneration [ID3983]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 8 January 2026.

    Technology appraisal guidance
    In consultation

  9. Port Delivery platform with ranibizumab for treating wet age-related macular degeneration [ID3983]

    Awaiting development Reference number: GID-TA10879 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Non-Hodgkin's lymphoma: rituximab subcutaneous injection (ESNM46)

    Summary of the evidence on rituximab subcutaneous injection for non-Hodgkin's lymphoma in adults to inform local NHS planning and decision-making

    Evidence summary
    Published
    9 September 2014

  11. Entrectinib for treating NTRK fusion-positive solid tumours (TA644)

    Evidence-based recommendations on entrectinib (Rozlytrek) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children over 12 years.

    Technology appraisal guidance
    Published
    12 August 2020
    View recommendations

    Sections for TA644

  12. Evidence on the safety and efficacy of artificial iris implant insertion for acquired aniridia is limited in quantity and quality. Therefore, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research.  Find out  what special arrangements mean on the NICE website .

    Give patients clear information to support shared decision making , including NICE's information for the public . Ensure...

    Research recommendation
    Published
    10 August 2020

  13. Tixagevimab plus cilgavimab for preventing COVID-19 (TA900)

    Evidence-based recommendations on tixagevimab plus cilgavimab (Evusheld) for preventing COVID-19 in adults.

    Technology appraisal guidance
    Published
    14 June 2023
    View recommendations

    Sections for TA900

  14. The evidence on percutaneous insertion of a cerebral protection device to prevent cerebral embolism during TAVI raises no major safety concerns other than those associated with the TAVI procedure. However, the evidence on efficacy for preventing TAVI-related stroke is inconclusive. Therefore, this procedure should only be used with  special arrangements   for clinical governance, consent, and audit or research.

    Inform the clinical governance leads in their NHS trusts. Ensure that patients and their carers understand the procedure's safety and...

    Research recommendation
    Published
    15 November 2019

  15. NICE committee meetings

    NICE public committee meetings supports our commitment to having processes in place that are rigorous, open, and transparent.